^
PD-L1 expression
Nasopharyngeal Carcinoma
sintilimab
Sensitive: C2 – Inclusion Criteria
Front Immunol - 3 weeks
PD-L1 expression
Nasopharyngeal Carcinoma
AK104
Sensitive: C3 – Early Trials
SITC 2021 - 3 weeks
No biomarker
Nasopharyngeal Carcinoma
toripalimab
Sensitive: A1 - Approval
No biomarker
Nasopharyngeal Carcinoma
GC
Sensitive: A2 - Guideline
No biomarker
Nasopharyngeal Carcinoma
carboplatin + paclitaxel
Sensitive: A2 - Guideline
No biomarker
Nasopharyngeal Carcinoma
DP
Sensitive: A2 - Guideline
No biomarker
Nasopharyngeal Carcinoma
TPF
Sensitive: A2 - Guideline
No biomarker
Nasopharyngeal Carcinoma
cetuximab
Sensitive: A2 - Guideline
No biomarker
Nasopharyngeal Carcinoma
oxaliplatin
Sensitive: A2 - Guideline
No biomarker
Nasopharyngeal Carcinoma
doxorubicin hydrochloride
Sensitive: A2 - Guideline
No biomarker
Nasopharyngeal Carcinoma
ifosfamide
Sensitive: A2 - Guideline
No biomarker
Nasopharyngeal Carcinoma
vinorelbine tartrate
Sensitive: A2 - Guideline
No biomarker
Nasopharyngeal Carcinoma
irinotecan
Sensitive: A2 - Guideline
No biomarker
Nasopharyngeal Carcinoma
capecitabine
Sensitive: A2 - Guideline
No biomarker
Nasopharyngeal Carcinoma
5-fluorouracil
Sensitive: A2 - Guideline
No biomarker
Nasopharyngeal Carcinoma
docetaxel
Sensitive: A2 - Guideline
No biomarker
Nasopharyngeal Carcinoma
paclitaxel
Sensitive: A2 - Guideline
No biomarker
Nasopharyngeal Carcinoma
nedaplatin
Sensitive: A2 - Guideline
No biomarker
Nasopharyngeal Carcinoma
cisplatin
Sensitive: A2 - Guideline
No biomarker
Nasopharyngeal Carcinoma
cisplatin + 5-fluorouracil
Sensitive: A2 - Guideline
No biomarker
Nasopharyngeal Carcinoma
cisplatin + paclitaxel + epirubicin
Sensitive: A2 - Guideline
No biomarker
Nasopharyngeal Carcinoma
cisplatin + docetaxel
Sensitive: A2 - Guideline
No biomarker
Nasopharyngeal Carcinoma
cisplatin + paclitaxel
Sensitive: A2 - Guideline
No biomarker
Nasopharyngeal Carcinoma
cetuximab
Sensitive: A2 - Guideline
No biomarker
Nasopharyngeal Carcinoma
carboplatin + gemcitabine
Sensitive: A2 - Guideline
No biomarker
Nasopharyngeal Carcinoma
carboplatin
Sensitive: A2 - Guideline
No biomarker
Nasopharyngeal Carcinoma
ADX-2191
Sensitive: A2 - Guideline
No biomarker
Nasopharyngeal Carcinoma
gemcitabine
Sensitive: A2 - Guideline
PD-L1 expression
Nasopharyngeal Carcinoma
pembrolizumab
Sensitive: C1 - Off-label
PD-L1 expression
Nasopharyngeal Carcinoma
AK105
Sensitive: C2 – Inclusion Criteria
CCR4 overexpression
Nasopharyngeal Carcinoma
FLX475
Sensitive: C3 – Early Trials
CCR4 overexpression
Nasopharyngeal Carcinoma
pembrolizumab + FLX475
Sensitive: C3 – Early Trials
PD-L1 expression
Nasopharyngeal Carcinoma
AB122
Sensitive: C3 – Early Trials
KLF4 overexpression
Nasopharyngeal Carcinoma
cetuximab
Resistant: C3 – Early Trials
Chr amplification(11)(q13)
Nasopharyngeal Carcinoma
toripalimab
Resistant: C3 – Early Trials
ETV6 amplification
Nasopharyngeal Carcinoma
toripalimab
Resistant: C3 – Early Trials
PD-L1 overexpression
Nasopharyngeal Carcinoma
AB122
Sensitive: C3 – Early Trials
HAVCR2 expression
Nasopharyngeal Carcinoma
PDR001
Sensitive: C3 – Early Trials
LAG3 expression
Nasopharyngeal Carcinoma
PDR001
Sensitive: C3 – Early Trials
IFNG expression
Nasopharyngeal Carcinoma
PDR001
Sensitive: C3 – Early Trials
RARS1-MAD1L1 fusion
Nasopharyngeal Carcinoma
cisplatin
Resistant: C4 – Case Studies
SATB1 overexpression
Nasopharyngeal Carcinoma
cisplatin
Resistant: D – Preclinical